 |
148 Diseases |  |
56 Trials |
|
56 Trials |  |
3630 News |  |
| «12...29303132333435363738394041» |
- | Januvia (sitagliptin) / Merck (MSD)
Enrollment change: Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes (clinicaltrials.gov) - Nov 12, 2012
P3, N=36, Completed, Sponsor: Laval University
N=30 --> 36
- || Januvia (sitagliptin) / Merck (MSD)
Trial completion: Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes (clinicaltrials.gov) - Nov 12, 2012
P3, N=36, Completed, Sponsor: Laval University
N=30 --> 36 Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
New P1 trial: Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis (clinicaltrials.gov) - Nov 1, 2012
P1, N=10, Recruiting, Sponsor: Nemours Children's Clinic
- | Januvia (sitagliptin) / Merck (MSD)
New P2 trial: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (clinicaltrials.gov) - Oct 31, 2012
P2, N=74, Recruiting, Sponsor: Indiana University
- exenatide DUROS subcutaneous delivery system (ITCA 650) / Servier, i20 Therap
Trial initiation date: A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Oct 17, 2012
P3, N=0, Withdrawn, Sponsor: Intarcia Therapeutics
Recruiting --> Completed Initiation date: Jul 2012 --> Feb 2013
- Nesina (alogliptin) / Takeda, Januvia (sitagliptin) / Merck (MSD)
Trial initiation date: DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=500, Not yet recruiting, Sponsor: Nagaoka Red Cross Hospital
Initiation date: Jul 2012 --> Feb 2013 Initiation date: May 2012 --> Oct 2012
- ||||| Janumet (metformin/sitagliptin) / Merck (MSD), Januvia (sitagliptin) / Merck (MSD)
Combination therapy: A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) (clinicaltrials.gov) - Oct 16, 2012
P4, N=5500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
New P3 trial, Monotherapy: Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020) (clinicaltrials.gov) - Oct 8, 2012
P3, N=410, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Januvia (sitagliptin) / Merck (MSD)
Trial initiation date: Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation (clinicaltrials.gov) - Oct 4, 2012
P3, N=36, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: May 2012 --> Oct 2012 Initiation date: Jul 2012 --> Oct 2012
- Januvia (sitagliptin) / Merck (MSD)
Enrollment open: Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation (clinicaltrials.gov) - Oct 4, 2012
P3, N=36, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Jul 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes (clinicaltrials.gov) - Oct 3, 2012
P4, N=90, Completed, Sponsor: Emory University
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Enrollment change: Sitagliptin in Renal Transplant Recipients (clinicaltrials.gov) - Sep 20, 2012
P4, N=25, Completed, Sponsor: University of Oslo School of Pharmacy
Not yet recruiting --> Completed N=14 --> 25
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: Sitagliptin in Renal Transplant Recipients (clinicaltrials.gov) - Sep 20, 2012
P4, N=25, Completed, Sponsor: University of Oslo School of Pharmacy
N=14 --> 25 Recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
New P4 trial: CGM-VISIT: Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function (clinicaltrials.gov) - Sep 16, 2012
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Januvia (sitagliptin) / Merck (MSD)
Clinical: Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) (clinicaltrials.gov) - Sep 6, 2012
P3, N=870, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=105 --> 870
- ||||| Januvia (sitagliptin) / Merck (MSD)
Enrollment closed: TECOS: Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (clinicaltrials.gov) - Aug 13, 2012
P3, N=14000, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=105 --> 870 Recruiting --> Active, not recruiting
- ||||||| Trulicity (dulaglutide) / Eli Lilly
Trial completion: A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin (clinicaltrials.gov) - Aug 8, 2012
P2/3, N=1566, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Enrollment open: Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=40, Recruiting, Sponsor: Niigata Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Onglyza (saxagliptin) / AstraZeneca
Clinical: Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp" (clinicaltrials.gov) - Aug 6, 2012
P4, N=12, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- Natrecor (nesiritide) / J&J, Januvia (sitagliptin) / Merck (MSD)
Biomarker, Trial initiation date: Pharmacogenetics of Ace Inhibitor-Associated Angioedema (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=64, Recruiting, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting Initiation date: Aug 2011 --> Nov 2011
- Natrecor (nesiritide) / J&J, Januvia (sitagliptin) / Merck (MSD)
Biomarker, Enrollment open: Pharmacogenetics of Ace Inhibitor-Associated Angioedema (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=64, Recruiting, Sponsor: Vanderbilt University
Initiation date: Aug 2011 --> Nov 2011 Not yet recruiting --> Recruiting
- ||||||| Tanzeum (albiglutide) / GSK
Trial completion: A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. (clinicaltrials.gov) - Aug 1, 2012
P3, N=507, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Bydureon (exenatide XR once-weekly) / AstraZeneca
New P3 trial: DURATION-NEO-2: Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jul 26, 2012
P3, N=360, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- ||| Januvia (sitagliptin) / Merck (MSD)
Trial completion: NEEDS: Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402) (clinicaltrials.gov) - Jul 16, 2012
P=N/A, N=726, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Trial initiation date, Bariatric surgery: Treatment of Diabetes After Gastric Bypass With Sitagliptin (clinicaltrials.gov) - Jul 5, 2012
P=N/A, N=42, Recruiting, Sponsor: Blandine Laferrere, MD
Recruiting --> Completed Initiation date: Apr 2012 --> Jul 2012
- Januvia (sitagliptin) / Merck (MSD)
Trial initiation date: Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy (clinicaltrials.gov) - Jul 5, 2012
P=N/A, N=20, Not yet recruiting, Sponsor: University of Vermont
Initiation date: Apr 2012 --> Jul 2012 Initiation date: Feb 2012 --> Sep 2012
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: SPHINX: Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome (clinicaltrials.gov) - Jun 27, 2012
P=N/A, N=82, Completed, Sponsor: VU University Medical Center
Initiation date: Feb 2012 --> Sep 2012 Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Enrollment change, IO biomarker: DPPIVinHIV: Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV (clinicaltrials.gov) - Jun 21, 2012
P2/3, N=20, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed N=30 --> 20
- Januvia (sitagliptin) / Merck (MSD)
Trial completion, IO biomarker: DPPIVinHIV: Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV (clinicaltrials.gov) - Jun 21, 2012
P2/3, N=20, Completed, Sponsor: Washington University School of Medicine
N=30 --> 20 Active, not recruiting --> Completed
- ||||| Januvia (sitagliptin) / Merck (MSD)
New P2 trial: Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 (clinicaltrials.gov) - Jun 12, 2012
P2, N=220, Completed, Sponsor: Novartis Pharmaceuticals
- ||||||| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Trial completion: The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial) (clinicaltrials.gov) - Jun 11, 2012
P3, N=756, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Enrollment change: "Effect of Dipeptidyl Peptidase IV After Diets in n (clinicaltrials.gov) - May 23, 2012
P=N/A, N=45, Completed, Sponsor: University of Sao Paulo General Hospital
Active, not recruiting --> Completed N=30 --> 45
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: "Effect of Dipeptidyl Peptidase IV After Diets in n (clinicaltrials.gov) - May 23, 2012
P=N/A, N=45, Completed, Sponsor: University of Sao Paulo General Hospital
N=30 --> 45 Enrolling by invitation --> Completed
- |||||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
New P3 trial: Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes (clinicaltrials.gov) - May 16, 2012
P3, N=425, Completed, Sponsor: LG Life Sciences
- Januvia (sitagliptin) / Merck (MSD)
Enrollment closed, Combination therapy: REPAIR-T1D: Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes (clinicaltrials.gov) - May 13, 2012
P2, N=54, Active, not recruiting, Sponsor: Sanford Health
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- ||||| Januvia (sitagliptin) / Merck (MSD)
Enrollment change: Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) (clinicaltrials.gov) - May 3, 2012
P3, N=75, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting N=95 --> 75
- ||||||| Januvia (sitagliptin) / Merck (MSD)
Trial completion: Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) (clinicaltrials.gov) - May 3, 2012
P3, N=75, Completed, Sponsor: Novartis
N=95 --> 75 Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
Enrollment change, Monotherapy: OPTIMA: Glycemic Holter Study (Continuous Glucose Monitoring) - (clinicaltrials.gov) - May 2, 2012
P4, N=36, Completed, Sponsor: Novartis
Active, not recruiting --> Completed N=50 --> 36
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion, Monotherapy: OPTIMA: Glycemic Holter Study (Continuous Glucose Monitoring) - (clinicaltrials.gov) - May 2, 2012
P4, N=36, Completed, Sponsor: Novartis
N=50 --> 36 Recruiting --> Completed
- |||||||||| Januvia (sitagliptin) / Merck (MSD)
New P3 trial, Combination therapy: A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254) (clinicaltrials.gov) - May 1, 2012
P3, N=460, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Januvia (sitagliptin) / Merck (MSD)
New P3 trial, Combination therapy: A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) (clinicaltrials.gov) - May 1, 2012
P3, N=460, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Nesina (alogliptin) / Takeda, Januvia (sitagliptin) / Merck (MSD)
Clinical: DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=500, Not yet recruiting, Sponsor: Nagaoka Red Cross Hospital
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105) (clinicaltrials.gov) - Apr 26, 2012
P2, N=251, Completed, Sponsor: Merck
Recruiting --> Completed Active, not recruiting --> Completed
- |||| PF-04991532 / Pfizer
Trial completion: Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 26, 2012
P2, N=266, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed
- | Trulicity (dulaglutide) / Eli Lilly
Trial completion: A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes (clinicaltrials.gov) - Apr 25, 2012
P1, N=32, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed Active, not recruiting --> Completed
- |||| PF-04991532 / Pfizer
Trial completion: Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 25, 2012
P2, N=301, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Trial completion, Monotherapy: The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial (clinicaltrials.gov) - Apr 22, 2012
P3, N=678, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
New P1 trial: A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142) (clinicaltrials.gov) - Apr 18, 2012
P1, N=22, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Januvia (sitagliptin) / Merck (MSD)
Enrollment change: Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome (clinicaltrials.gov) - Apr 11, 2012
P4, N=24, Completed, Sponsor: Vanderbilt University
Active, not recruiting --> Completed N=96 --> 24
- ||||||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes (clinicaltrials.gov) - Apr 3, 2012
P3, N=986, Completed, Sponsor: Boehringer Ingelheim
N=96 --> 24 Active, not recruiting --> Completed